Document:

EXHIBIT 10.20

                                    AGREEMENT

This Agreement dated as of the 30 day of December, 1999, between

               COLUMBIA LABORATORIES INC., a corporation organized
          And existing under and by virtue of the laws of the State of
         Delaware, having an office at 2875 NE 191st Street, Suite 400,
       Aventura, FL 33180, USA (hereinafter referred to as the "Company")

and

           DOMINIQUE DE ZIEGLER, with offices at Hopital deNyon, Nyon
          1261, Switzerland (hereinafter referred to as "de Ziegler")

                              W I T N E S S E T H:

         WHEREAS, the Company is and will be engaged in the development,
testing, registration, manufacture, licensing and sale of pharmaceutical
products; and

         WHEREAS, de Ziegler is a physician with Board certification in
obstetrics, gynecology and reproductive endocrinology and, by reason of this and
his other knowledge, skill and ability, is uniquely qualified to aid the Company
in the development, testing, registration, manufacture, licensing and sale of
pharmaceutical products; and

         WHEREAS, the Company is desirous of establishing a business
relationship with de Ziegler to provide assistance to the Company in the
development, testing, registration, manufacture, licensing and sale of
pharmaceutical products and de Ziegler is desirous of assisting the Company in
the development, testing, registration, manufacture, licensing and sale of
pharmaceutical products; and

         WHEREAS, the Company and de Ziegler desire to enter into this Agreement
so the rights, duties, benefits and obligations of each will be fully set forth
herein; and

                  NOW, THEREFORE, in consideration of the mutual promises
contained by each party to the other, and for other good and valuable
consideration, the Company and de Ziegler agree as follows:

<PAGE>

         1.       NATURE OF ENGAGEMENT

                  The Company and de Ziegler agree to establish the following
professional and business relationship:

                  a. de Ziegler shall be employed by the Company to provide
services at its Paris, France offices; and

                  b. de Ziegler shall be employed by the Company to perform
medical research at his Nyon, Switzerland medical practice; and

                  c. de Ziegler's workweek shall be divided between Paris,
France and Nyon, Switzerland as follows: twenty (20%) percent France and eighty
(80%) percent Switzerland.

         2.       TERM

                  a. The term of this Agreement shall be for a period of one (1)
year from the date hereof ("Initial Period"), unless sooner terminated in
accordance with the terms and conditions set forth herein.

                  b. At the end of the Initial Period, upon the mutual agreement
of de Ziegler and the Company, the term of this Agreement may be extended for an
additional period of years ("Renewal Period(s)"), either upon the terms and
conditions set forth herein, or upon any other terms and conditions as may be
mutually agreed in writing between de Ziegler and the Company. The foregoing
provisions of this Subparagraph 2(b) notwithstanding, this Agreement shall
terminate at the end of the Initial Period or Renewal Period(s), as the case may
be, as provided for in this Paragraph 2, and there shall not be any automatic
renewal or other similar extension of the term of employment.

         3.       DISABILITY

                  If, during the effective term of this Agreement, de Ziegler
shall become unable to perform his duties as provided for herein by reason of
illness or injury, for a consecutive period of ninety (90) days ("Disability
Period"), the Company may, on thirty (30) days' written notice to de Ziegler,
immediately terminate this Agreement, with no further obligation to de Ziegler.

         4.       TERMINATION

                  a. Company Termination for Cause

                                       2
<PAGE>

                           This Agreement may be immediately terminated by the
Company for cause at any time, upon written notice to de Ziegler, after which
all obligations of the Company to de Ziegler shall thereupon cease. For purposes
of this Agreement, the term "Cause" when used in reference to the termination of
this Agreement, shall mean only any or all of the following:

                           i. Failure on the part of de Ziegler to follow
material instructions or policy of the Board of Directors given or adopted in
good faith, or carry out an agreed policy or course of action as determined by
the Board of Directors or a committee of the Board of Directors, any or all of
which may be to the detriment of the Company, provided the Company shall serve
written notice to de Ziegler of his breach of this Subparagraph 4(a)(i) setting
forth particularly de Ziegler's conduct creating the breach, and that de Ziegler
shall cure such breach within thirty (30) days of such written notice and the
failure to do so will then permit the Company to implement the provisions of
this Paragraph 4; or

                           ii. Willful misconduct or gross negligence of de
Ziegler in connection with the performance of his duties and services; or

                           iii. The termination of this Agreement shall
automatically result in the cancellation of the Company's business relationship
with de Ziegler and his medical practice.

b.       Termination by de Ziegler

                           de Ziegler may terminate this Agreement without
penalty of any kind upon ninety (90) days prior written notice to the Company.

         5.       DUTIES

                  a. de Ziegler shall perform the following duties in connection
with his engagement, all of which shall be subject to the paramount direction of
the Board of Directors:

                           i. To serve as a Member of the Board of Directors of
the Company;

                              i. To serve as Director of Research and
Development;

                  ii. To assist the Company in its business affairs and
scientific dealings relating to the development, testing, registration,
manufacture, licensing and sale

                                       3
<PAGE>

of pharmaceutical products, as well as in the Company's dealings with other
companies; and

           iii. To undertake and conduct research for the Company within his
private medical practice in Nyon, Switzerland, as may be given to him from time
to time by the Board of Directors.

                  b. de Ziegler shall devote his best efforts and skills to the
affairs of the Company, and to the performance of the duties set forth in
Subparagraph 5(a). de Ziegler shall not participate in any outside business
activity that will either interfere with or be a conflict of interest with the
performance of his duties pursuant to this Agreement. Notwithstanding the
foregoing, de Ziegler will be permitted to maintain a private practice in Nyon,
Switzerland.

         6.       COMPENSATION

                  a. de Ziegler shall receive for the performance of his duties
and services on behalf of the Company, as provided for herein, annual
compensation of approximately Two Hundred Ten Thousand (US$210,000.00) United
States Dollars, which shall be paid by the Company to de Ziegler in monthly
installments.

                  b. The aforesaid compensation shall be allocated twenty (20%)
percent to de Ziegler's employment in France and eighty (80%) percent to his
employment contract services in Nyon, Switzerland. The compensation paid to de
Ziegler in Switzerland shall include a lodging allowance of approximately
Thirty-Six Thousand (US$36,000.00) United States Dollars. Payment for the Nyon,
Switzerland services shall be made to his medical practice.

                  c. de Ziegler may receive a bonus if it is determined to be
warranted by the Board of Directors in their sole discretion.

         7.       FRINGE BENEFITS

                  In addition to the compensation set forth in Paragraph 6
above, de Ziegler shall be entitled to receive the following benefits virtue of
his employment by the Company in France;

                  a. Any benefits under group hospitalization, health, dental
care or sick leave plan, life or other insurance or death benefit plan, travel
or accident insurance, or contingent compensation plan, or any other present or
future plan, including any

                                       4
<PAGE>

qualified retirement plan, for which any executive of the Company is or shall
become eligible; and

                  b. A vacation of up to four (4) weeks in each year, at such
time or times as shall be approved by the Company, and which approval shall not
be unreasonably refused. Full compensation shall be paid to de Ziegler and his
medical practice during any such vacation period; and

                  c. de Ziegler may incur and shall be reimbursed for reasonable
expenses which are related to the Company's business, including expenses for
entertainment, travel and similar items ("Approved Reimbursable Expenses"). All
such reimbursement of Approved Reimbursable Expenses shall be made within sixty
(60) days of receipt by the Company from de Ziegler of an itemized account and
proper substantiation of such Approved Reimbursable Expenses. In order to
facilitate the payment of Approved Reimbursable Expenses, the Company may
furnish de Ziegler with Company acquired credit cards; and

                  d. de Ziegler shall be given an office with secretarial help
and any and all reasonable facilities and services as to be suitable with his
position as Director of Research and Development so as to assist him in the
performance of his duties and activities; and

                  e. The Company shall provide de Ziegler with an apartment in
Paris, France, which shall have a maximum rent per month of Eighteen Thousand
(18,000) French francs. Notwithstanding the foregoing, de Ziegler may lease any
apartment in Paris, France and the Company will pay monthly rental stipend to de
Ziegler of no more than Eighteen Thousand (18,000) French francs.

                  f. If de Ziegler's employment shall be terminated by the
Company whatsoever the reason or cause, in addition to any benefits required to
be paid by French law, de Ziegler's medical practice shall continue to receive
monthly payments due it for a period of twelve (12) months.

         8.       DISCLOSURE OR INFORMATION

                  De Ziegler recognizes and acknowledges that during the course
of his professional relationship with the Company he will have access to certain
confidential information and that such information constitutes valuable, special
and unique property

                                       5
<PAGE>

of the Company. During the term of this Agreement and following termination
thereof, de Ziegler will not disclose such information, including any trade
secrets or confidential information of the Company obtained during the course of
his relationship with the Company, except any information as may have become
part of the public domain through no fault of de Ziegler.

                   De Ziegler and the Company acknowledge it would be very
difficult or impossible to measure the damages resulting from a breach of this
Paragraph 8, and that any such breach would cause immediate and irreparable
harm. Therefore, in consequent of the foregoing, de Ziegler hereby agrees that
any breach or threatened breach by him of any provision of this Paragraph 8
shall entitle the Company, in addition to any other legal remedies available to
it, to obtain from any court of competent jurisdiction a temporary and permanent
injunction in order to enjoin such breach or threatened breach without the
necessity on the part of the Company, in any application for such injunctive
relief, to show immediate and irreparable harm, which would be a requirement of
such an application absent this covenant waiving those requirements. de Ziegler
also covenants the service of any papers to commence any legal proceedings
including proceedings to obtain injunctive relief, may be done by utilizing
Federal Express in lieu of any other form of personal delivery of the process of
orders of the Court and upon doing so the service and notice provisions for the
commencement of legal proceedings shall be satisfied.

         9.       DEATH DURING EMPLOYMENT

                  If de Ziegler dies during the term of this Agreement, the
Company shall pay compensation which would otherwise be payable to de Ziegler
and to his medical practice for a period of six (6) months from the date of his
death under this Agreement. Said sum shall be paid to the surviving spouse of de
Ziegler, or if there is no surviving spouse, then to his surviving children in
equal shares, or if there are none, then to his estate.

         10.      NOTICES

                  Any notice required or permitted to be given under this
Agreement shall be sufficient if in writing and actually delivered, or if sent
either by Federal Express, or

                                       6
<PAGE>

postage prepaid, by certified mail, return receipt requested, with a copy by
ordinary mail to the addresses below:

         As to the Company:                    2875 NE 191st Street, Suite 400
                                               Aventura, FL 33180, USA

         As to de Ziegler:                     Hopital deNyon
                                               Nyon 1261, Switzerland

Or such other address as either party shall designate by written notice to the
other.

         11.      ASSIGNMENT

                  The rights and obligations of the Company under this Agreement
shall inure to the benefit of and shall be binding upon the successors and
assigns of the Company. de Ziegler acknowledges the services to be rendered by
him are unique and personal and, accordingly, he may not assign any of his
rights, duties, obligations or benefits under this Agreement.

         12.      ENTIRE AGREEMENT

                  This Agreement contains the entire agreement and understanding
of the Company and de Ziegler with respect to the subject matter hereof, and
shall incorporate, merge and supercede all prior agreements and understandings
had between the Company and de Ziegler, either oral or written, if any. No
modification, change or amendment to this Agreement shall be binding upon the
Company or de Ziegler unless the same is in writing, and signed by both parties.

         13.      MISCELLANEOUS

                  a. This Agreement and the implementation of it shall be
subject to and governed by the laws of the State of New Jersey and any legal
proceedings relating to (i) the interpretation or enforcement of any of the
provisions of this Agreement, or (ii) any dispute relating to the employment
relationship created by this Agreement shall, with the exception of a dispute
under Paragraph 8 of this Agreement, be resolved by arbitration before the
American Arbitration Association in their New Jersey offices, in accordance with
their rules then in effect. Disputes under Paragraph 8 of this Agreement shall
only be brought in the Courts of the State of New Jersey.

                                       7
<PAGE>

                  b. The paragraph headings contained herein are for references
purposes only and shall not in any way affect the meaning or the interpretation
of this Agreement.

                  c. The failure of any provision of this Agreement shall in no
matter affect the right to enforce the remainder of this Agreement, and the
waiver by either the Company or de Ziegler of any breach of any provision of
this Agreement shall not be construed to be a waiver by the Company or de
Ziegler of any succeeding breach of such provision or a waiver by such party of
any breach of any other provision of this Agreement.

         IN WITNESS WHEREOF, the parties here to have executed this Agreement as
of the date first above written.

                                                COLUMBIA LABORATORIES, INC.

                                                By: /s/ William Bologna
                                                    ----------------------------
                                                    William Bologna, Chairman

                                                /s/ Dominique de Ziegler
                                                    ----------------------------
                                                Dominique de Ziegler

                                       8EXHIBIT 10.21

                        SETTLEMENT AGREEMENT AND RELEASE

         THIS SETTLEMENT AGREEMENT AND RELEASE ("Agreement") is made by and
between Columbia Laboratories, Inc., Columbia Laboratories (Bermuda) Ltd.
("Columbia"), on the one hand, and Lake Consumer Products, Inc., f/k/a Lake
Pharmaceutical, Inc. ("Lake"), on the other. (The aforementioned parties may
hereinafter be collectively referred to as the "Settling Parties").

                                   WITNESSETH:

         WHEREAS, Columbia and Lake had a business relationship ("Relationship")
regarding a spermicidal gel product of Columbia ("Product").

         WHEREAS, Columbia and Lake entered into a License and Distribution
Agreement effective as of July 1, 1994 regarding Columbia's spermicidal gel
product ("Columbia/Lake Agreement").

         WHEREAS, a dispute arose between Columbia and Lake with respect to the
Columbia/Lake Agreement and Relationship, ("Dispute") leading to claims by
Columbia and Lake in actions captioned COLUMBIA LABORATORIES, INC. AND COLUMBIA
LABORATORIES (BERMUDA) LTD V. LAKE PHARMACEUTICAL, INC., United States District
Court for the Southern District of Florida Case No. 97-3378-CIV-Gold ("Florida
Action") and LAKE CONSUMER PRODUCTS, INC. V. COLUMBIA LABORATORIES, INC., United
States District Court for the Northern District of Illinois Case No. 97 C 7951,
transferred to the United States District Court for the Southern District of
Florida under case no. 98-1091-CIV-Graham ("Illinois Action") (the Florida
Action and the Illinois Action may collectively be referred to as the
"Actions").

         WHEREAS, the Settling Parties desire to settle and resolve all issues
related to the Product, the Relationship, the Columbia/Lake Agreement, the
Dispute and the Actions, as set forth below;

         NOW THEREFORE, for good and valuable consideration, the sufficiency of
which is hereby acknowledged, the Settling Parties hereby agree as follows:

                        I. LAKE RELEASE AND UNDERTAKINGS

         1. In consideration of Columbia's promises, covenants, payments,
representations, and warranties under this Agreement, Lake, its officers,
directors and employees and its assigns and all persons claiming by, through,
for or under it or on its behalf, and each of them, jointly and severally hereby
fully, unconditionally, and forever release Columbia, and its respective present
and past subsidiaries, parents, and other affiliated or related entities, and
their respective predecessors, successors, assigns, officers, directors, agents,
shareholders, employees, insurers, counsel and representatives, and each of
them, of, from and against any and all claims, debts, demands, liabilities,
fees, costs, expenses, damages and/or causes of action whatsoever, whether known
or unknown, whether past, present, or future, accrued or unaccrued, that arise
from or relate to the Relationship, including but not limited to (a) claims that
arise from or relate to the Product, the Columbia/Lake Agreement, or the
Dispute, and (b) claims that were or could have been raised in the Actions. This
specifically includes, but is not limited to, a release as to all issues
relating to the Product, its current uses and claims and any of the Product's
actual or potential future uses and claims, including without limitation
STD-related uses or claims, as well as any and all causes of action, debts,
demands, liabilities, fees, costs, expenses, damages and/or defenses whatsoever
sounding in fraud.

         2. In further consideration of Columbia's promises, covenants,
payments, representations, and warranties under this Agreement, Lake shall, upon
(a) the Columbia Stock Issuance, and (b) payment of the first installment of the
Columbia Payment, agree to the entry of a stipulation dismissing with prejudice
its claims against Columbia in any of the Actions that are pending.

<PAGE>

         3. In further consideration of Columbia's promises, covenants,
payments, representations, and warranties under this Agreement, Lake shall, upon
(a) the Columbia Stock Issuance, and (b) payment of the first installment of the
Columbia Payment, agree to the termination and buy-out of the Columbia/Lake
Agreement as set forth in Article III of this Agreement.

         II. COLUMBIA PAYMENT, STOCK ISSUANCE, RELEASE, AND UNDERTAKINGS

         1. In consideration of Lake's promises, covenants, representations, and
warranties under this Agreement, Columbia will pay to Lake the sum of One
Million Two Hundred Thousand Dollars ($1,200,000) as follows: (i) Six Hundred
Thousand Dollars ( $600,000 ) in cash in five (5) consecutive monthly
installments, the first installment to be paid by check in the sum of Two
Hundred Thousand Dollars ($200,000) within three (3) business days of the
execution of this Agreement and then One Hundred Thousand Dollars ($100,000) per
month by check on the monthly anniversary of the first payment for the following
four (4) consecutive months ("Columbia Payment"); and (ii) Six Hundred Thousand
Dollars in the form of the common capital stock of Columbia Laboratories, Inc.,
valued at $11 1/8th, the February 25,2000 closing price as published in the
February 26, 2000 New York Times, to be delivered to Lake within three (3)
business days of the execution of this Agreement ("Columbia Stock Issuance").
After the Columbia Stock Issuance, Columbia will, at Columbia's cost, within
ninety (90) days of the execution date of this Agreement, be required to file a
registration statement with the Securities and Exchange Commission on a form
suitable for resale of the common capital stock to be issued to Lake, and
Columbia shall use its commercially reasonable best efforts to cause such
registration statement to become effective, and to maintain the effectiveness of
the registration statement for not less than 180 days, and shall supply Lake
with sufficient copies of the related prospectus so as to permit Lake to satisfy
its prospectus delivery requirements in connection with resale of the stock.

         2. In further consideration of Lake's promises, covenants,
representations, and warranties under this Agreement, Columbia, its officers,
directors and employees and its assigns and all persons claiming by, through,
for or under it or on its behalf, and each of them, jointly and severally hereby
fully, unconditionally, and forever release Lake, and its respective present and
past subsidiaries, parents, and other affiliated or related entities, and their
respective predecessors, successors, assigns, officers, directors, agents,
shareholders, employees, insurers, counsel and representatives, and each of
them, of, from and against any and all claims, debts, demands, liabilities,
fees, costs, expenses, damages and/or causes of action whatsoever, whether known
or unknown, whether past, present, or future, accrued or unaccrued, that arise
from or relate to the Relationship, including but not limited to (a) claims that
arise from or relate to the Product, the Columbia/Lake Agreement, or the
Dispute, and (b) claims that were or could have been raised in the Actions. This
specifically includes, but is not limited to, a release as to all issues
relating to the Product, its current uses and claims and any of the Product's
actual or potential future uses and claims, including without limitation
STD-related uses or claims, as well as any and all causes of action, debts,
demands, liabilities, fees, costs, expenses, damages and/or defenses whatsoever
sounding in fraud.

         3. In further consideration of Lake's promises, covenants,
representations, and warranties under this Agreement, Columbia shall agree to
the entry of a stipulation dismissing with prejudice its claims against Lake in
any of the Actions that are pending.

         4. In further consideration of Lake's promises, covenants,
representations, and warranties under this Agreement, Columbia shall agree to
the termination and buy-out of the Columbia/Lake Agreement as set forth in
Article III of this Agreement.

                     III. AGREEMENT BUY-OUT AND TERMINATION

         The Settling Parties agree that the Columbia/Lake Agreement is hereby
bought out and thereby terminated, with full legal force and effect, and
accordingly neither of the Settling Parties has any future rights or
responsibilities under the Columbia/Lake Agreement.

                       IV. WARRANTIES AND REPRESENTATIONS

         1. Each of the Settling Parties represents and warrants to the another
that it has never assigned to anyone any (or any portion) of the claims, debts,
demands, liabilities, expenses, damages, fees, costs and causes of action

                                       2
<PAGE>

which are the subject of this Agreement, and shall indemnify the other for any
claim made by reason of such assignment.

         2. Each of the Settling Parties represents and warrants to the other
that it has sought and received the advice of its respective attorneys prior to
entering into this Agreement and hereby acknowledges that it has read in full
this Agreement, agrees to each and every term and condition set forth herein,
and voluntarily agrees to be bound by same. Each of the Settling Parties also
represents and warrants that it has not relied upon any representation or lack
thereof by the other Party in reaching its decision to enter into this Agreement
except for those representations and warranties listed in Section IV herein. In
addition, Lake expressly acknowledges the possibility that the Product may, at
some point in the future, immediate or otherwise, acquire additional claims,
including but not limited to STD-related claims, and expressly acknowledges that
it is not relying on any representations, or lack thereof, by Columbia in that
regard in entering into this Agreement. Lake also expressly acknowledges that it
is not relying upon any representations by Columbia, or lack thereof, as to the
value or future value of the stock that it is receiving pursuant to Section II.
Lake also expressly acknowledges that it is not relying upon any disclosure by
Columbia or lack thereof in discovery in the Actions.

         3. Each of the Settling Parties represents that the terms and
conditions of this Agreement shall be kept confidential and will not be revealed
to any other person or entity, except upon order of Court or upon required
disclosure by the Settling Parties as provided by law or regulation, and except
as may be required in the ordinary course of business. Should Columbia choose to
seek an order sealing the files which relate in whole or in part to this
Agreement, Lake will not object.

                           V. PRODUCT LIABILITY CLAIMS

         The parties to this Settlement Agreement and Release are not releasing
each other for indemnification or contribution claims arising out of third party
consumer product liability or third party consumer tort claims concerning the
Product.

                                VI. MISCELLANEOUS

         It is understood and acknowledged by the Settling Parties that:

         1. The terms herein do not constitute an admission of liability on the
part of the Settling Parties;

         2. if any provision of this Agreement shall be invalid or
unenforceable, the remaining provisions hereof shall continue to be fully
effective, provided that such remaining provisions do not increase the
obligations or liabilities of the Settling Parties;

         3. the Agreement may be executed in any number of counterparts, each of
which when so executed shall be deemed to be an original, and such counterparts
together shall constitute and be one and the same instrument;

         4. the Agreement is the entire agreement among the Settling Parties,
supersedes and replaces any prior oral or written communications,
representations, or understandings concerning the terms of this Agreement, may
be modified only by an instrument in writing executed by the parties hereto, and
is effective as of the date of execution set forth below;

         5. the Agreement shall be binding upon and inure to the benefit of the
respective successors, assigns, and predecessors of the Settling Parties;

         6. except as otherwise provided herein, the representations,
warranties, covenants and agreements set forth in the Agreement will survive the
execution, delivery, and performance hereof;

         7. the headings contained in the Agreement are inserted for convenience
only and shall not affect the meaning or construction of any of the terms in the
Agreement;

         8. in any action brought to enforce the terms of this Agreement, the
prevailing party in such action shall be entitled to recover from the other
party all reasonable costs thereof, including reasonable attorneys' fees and
costs;

                                       3
<PAGE>

         9. the parties agree that the United States District Court for the
Southern District of Florida shall retain exclusive jurisdiction of the parties
for purposes of interpretation and enforcement of this Agreement; and

         10. this Agreement shall be construed and enforced in accordance with,
and governed by, the laws of the State of Florida, without regard to principles
governing choice of law.

    IN WITNESS WHEREOF, the Settling Parties have caused this Agreement to be
duly executed by its authorized officer on the date set forth below.

                                    Lake Consumer Products, Inc.

_________________                   By:  /s/ Gary J. Burns
                                         -----------------

                                         Its:  President
STATE OF ILLINOIS
                      SS:
COUNTY OF LAKE

                  I HEREBY CERTIFY that on this date before an officer duly
authorized in this State and County to take acknowledgments, personally appeared
Gary J. Burns, as (Title) President, on behalf of Lake Consumer Products, Inc.
f/k/a Lake Pharmaceutical, Inc. who acknowledged executing this Settlement
Agreement and Release freely and voluntarily, and is personally known to me or
produced the following as identification:

                  WITNESS my hand and official seal in the County and State
referenced above this 16th day of March, 2000.

                                                     /s/ Susan M. Kellogg
                                                     --------------------
                                                     Notary Public

                                                     Notary Stamp:

                                       4
<PAGE>

                                    Columbia Laboratories (Bermuda) Ltd.

_________________                   By:  /s/James J. Apostolakis
                                         ---------------------------------------
                                             Its:  President

STATE OF NEW YORK
                          SS:
COUNTY OF NEW YORK

                  I HEREBY CERTIFY that on this date before an officer duly
authorized in this State and County to take acknowledgments, personally appeared
James J. Apostolakis, as (Title) President, on behalf of Columbia Laboratories
(Bermuda), Ltd. who acknowledged executing this Settlement Agreement and Release
freely and voluntarily, and is personally known to me or produced the following
as identification:

                  WITNESS my hand and official seal in the County and State
referenced above this 16th day of March, 2000.

                                                     /s/Kenneth M. Swisstack
                                                     -----------------------
                                                     Notary Public

                                                     Notary Stamp:

                                       5
<PAGE>

                                    Columbia Laboratories, Inc.

_________________                   By:  /s/James J. Apostolakis
                                         -----------------------
                                             Its:  President

STATE OF NEW YORK
                                    SS:
COUNTY OF NEW YORK

                  I HEREBY CERTIFY that on this date before an officer duly
authorized in this State and County to take acknowledgments, personally appeared
James J. Apostolakis, as (Title) President, on behalf of Columbia Laboratories,
Inc. who acknowledged executing this Settlement Agreement and Release freely and
voluntarily, and is personally known to me or produced the following as
identification:
                  WITNESS my hand and official seal in the County and State
referenced above this 16th day of March, 2000.

                                                     /s/Kenneth M. Swisstack
                                                     -----------------------
                                                     Notary Public

                                                     Notary Stamp:

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]